HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Find → Understand → Decide

Soticlestat

Discovery priority: MEDIUM · POSSIBLE / INVESTIGATE

Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.

Why investigate?

Why stranded (event context): inadequate public evidence; strategic reprioritization

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN

Biology implicated: UNCLEAR · Failure context: CORPORATE/FINANCIAL

MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.

Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN

Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.

Existing buyer gates

Human Signal: UNKNOWN

Cheap Truth: UNKNOWN

Clean Rights: UNKNOWN

Market Pull: UNKNOWN

No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.

Evidence timeline

2026-08-19 · trial:NCT05309902

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Study not needed

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "33de855feea9ae21ca642e2b849aa2297321dc1563ce569832bd7871e13431f2",
  "metadata": {
    "complete": false,
    "content_hash": "4cabd429cb884ebeb9efe5893ed7344dfcca71cd4076988989429865aef061a0",
    "failed": false,
    "last_checked": 1790026983.0118148,
    "last_success": 1790026983.0118148,
    "live_verified": true,
    "scope": "AREA[OverallStatus]WITHDRAWN AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "4cabd429cb884ebeb9efe5893ed7344dfcca71cd4076988989429865aef061a0",
  "raw_path": "research/obz7_sources/4cabd429cb884ebeb9efe5893ed7344dfcca71cd4076988989429865aef061a0.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]WITHDRAWN AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT05309902"
}

2026-09-04 · trial:NCT05163314

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary data from TAK-935-3003 study is no longer necessary. Therefore, Takeda has made a decision to close this study

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "c5f3b4f34d1327cf3aa68bebc87893ad744274277d4a4d9b8909624ceb8ab70c",
  "metadata": {
    "complete": false,
    "content_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
    "failed": false,
    "last_checked": 1790026980.9308648,
    "last_success": 1790026980.9308648,
    "live_verified": true,
    "scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
  "raw_path": "research/obz7_sources/79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT05163314"
}

2026-09-04 · trial:NCT06422377

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Business decision unrelated to patient safety.

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: strategic reprioritization · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "e46db0172b1217eddeb68508bc7e377e2e8738a9b0e1c1ab85a420420e51bf5d",
  "metadata": {
    "complete": false,
    "content_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
    "failed": false,
    "last_checked": 1790026980.9308648,
    "last_success": 1790026980.9308648,
    "live_verified": true,
    "scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
  "raw_path": "research/obz7_sources/79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT06422377"
}

2026-09-04 · trial:NCT03635073

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary data from TAK-935-18-001 study is no longer necessary. Therefore, Takeda has made a decision to close this study

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "a87a4059abaeae12dafc2520df5cddd358a57c2c0aee672f3a97f83d085969fb",
  "metadata": {
    "complete": false,
    "content_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
    "failed": false,
    "last_checked": 1790026980.9308648,
    "last_success": 1790026980.9308648,
    "live_verified": true,
    "scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
  "raw_path": "research/obz7_sources/79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT03635073"
}

Freshness is claim-specific

Fetching an old filing today does not establish current ownership or program status.

pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.930865+00:00

clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.930865+00:00

clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.930865+00:00

clinicaltrials · STALE · AREA[OverallStatus]WITHDRAWN AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:03.011815+00:00

Registry observations (4)

NCT05163314 · TERMINATED · PHASE3 · Dravet Syndrome (DS); Lennox Gastaut Syndrome (LGS) · Trial sponsor Takeda

Reported aliases: TAK-935. Identity, treatment role and exposure require review.

NCT06422377 · TERMINATED · PHASE3 · Dravet Syndrome (DS); Lennox-Gastaut Syndrome (LGS) · Trial sponsor Takeda

Reported aliases: TAK-935. Identity, treatment role and exposure require review.

NCT03635073 · TERMINATED · PHASE2 · Epilepsy; Dravet Syndrome (DS); Lennox-Gastaut Syndrome (LGS) · Trial sponsor Takeda

Reported aliases: TAK-935. Identity, treatment role and exposure require review.

NCT05309902 · WITHDRAWN · PHASE1 · Healthy Volunteers · Trial sponsor Takeda

Reported aliases: TAK-935. Identity, treatment role and exposure require review.

Back to discovery